Apellis Pharmaceuticals, Inc. has admitted that Syfovre was unlikely to get past EU regulators and onto the market. Analysts had predicted that Europe would account for 40% of peak worldwide sales of the geographic atrophy therapy; with these now out of reach, ramping up sales in the US becomes vital.
Key Takeaways
- The geographic atrophy therapy Syfovre is likely to get a negative vote from the CHMP, Apellis believes
The company said it expects the Committee for Medicinal Products for Human Use (CHMP) to give a negative opinion on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?